First-Line Ibrutinib Plus Obinutuzumab vs Chlorambucil Plus Obinutuzumab for CLL/SLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Haematologica 2022 Sep 01;107(9)2108-2120, C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, J Novak, V Strugov, D Gill, JG Gribben, K Kwei, S Dai, E Hsu, JP Dean, IW FlinnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.